131I-CHI

**131I-CHI** is an investigational **radiopharmaceutical hydrogel embolization product** developed by **KaiBioTech** for **liver cancer**, particularly hepatocellular carcinoma. It consists of **iodine-131 embedded in chitosan-based polymer hydrogel microparticles** designed for **intra-arterial hepatic delivery** during interventional embolization. After administration through the hepatic artery, the microparticles lodge in tumor-feeding vasculature, producing a dual local effect of **arterial embolization** and **beta-radiation delivery** from iodine-131 to irradiate and destroy liver tumor tissue while limiting extrahepatic exposure. Available source material indicates Korean clinical-trial approval in **October 2013** and early clinical development consistent with **Phase 1** investigation.

Other names

iodine-131 chitosan hydrogel microparticlesiodine131 chitosan hydrogel microparticlesiodine 131 chitosan hydrogel microparticlesiodine-131 incorporated chitosan hydrogel microparticlesiodine131 incorporated chitosan hydrogel microparticlesiodine 131 incorporated chitosan hydrogel microparticles